<DOC>
	<DOCNO>NCT02736955</DOCNO>
	<brief_summary>This Phase 3b , rollover study provide subject complete Phase 3 valbenazine ( NBI-98854 ) study open-label access valbenazine ( fixed dos administer daily ) treatment TD valbenazine anticipate available commercially complete 72 week treatment . This study allow enrollment 75 medically stable male female subject TD previously participate complete NBI-98854-1304 ( Kinect 3 ) NBI-98854-1402 ( Kinect 4 ) Phase 3 study .</brief_summary>
	<brief_title>Rollover Study Continuing Valbenazine ( NBI-98854 ) Administration Treatment Tardive Dyskinesia</brief_title>
	<detailed_description />
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Movement Disorders</mesh_term>
	<mesh_term>Tetrabenazine</mesh_term>
	<criteria>Have participate complete NBI988541304 ( Kinect 3 ) NBI988541402 ( Kinect 4 ) Phase 3 study . Subjects childbearing potential must agree use hormonal two form nonhormonal contraception ( dual contraception ) consistently throughout study 30 day last dose valbenazine . If use maintenance medication ( ) schizophrenia schizoaffective disorder , mood disorder , condition , stable dos . Be general good health . Have adequate hearing , vision , language skill perform procedure specify protocol . Have negative urine drug screen amphetamine , barbiturate , benzodiazepine , phencyclidine , cocaine , opiates , cannabinoids . Have active , clinically significant unstable medical condition within 1 month prior screen . Have know history substance dependence , substance ( drug ) alcohol abuse . Have significant risk suicidal violent behavior . Have know history neuroleptic malignant syndrome . Have know history long QT syndrome cardiac arrhythmia . Have cancer diagnosis within 3 year prior screen ( exception allow ) . Have receive investigational drug within 30 day screen plan use investigational drug ( valbenazine ) study . Have blood loss â‰¥550 mL donate blood within 30 day prior Baseline . Have allergy , hypersensitivity , intolerance tetrabenazine . Are currently pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>